These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 26087295)

  • 21. Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty.
    DiazGranados CA; Dunning AJ; Robertson CA; Talbot HK; Landolfi V; Greenberg DP
    Vaccine; 2015 Aug; 33(36):4565-71. PubMed ID: 26187260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
    Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
    Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial.
    Cools HJ; Gussekloo J; Remmerswaal JE; Remarque EJ; Kroes AC
    J Med Virol; 2009 May; 81(5):908-14. PubMed ID: 19319953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.
    Hancock K; Veguilla V; Lu X; Zhong W; Butler EN; Sun H; Liu F; Dong L; DeVos JR; Gargiullo PM; Brammer TL; Cox NJ; Tumpey TM; Katz JM
    N Engl J Med; 2009 Nov; 361(20):1945-52. PubMed ID: 19745214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccine-specific antibody secreting cells are a robust early marker of LAIV-induced B-cell response in ferrets.
    Cherukuri A; Servat E; Woo J
    Vaccine; 2012 Jan; 30(2):237-46. PubMed ID: 22080173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.
    Roggelin L; Vinnemeier CD; Meyer S; Witte K; Marx L; Theeß W; Burchard GD; Rolling T; Cramer JP
    Hum Vaccin Immunother; 2015; 11(10):2370-5. PubMed ID: 26114800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults.
    Hakim H; Allison KJ; Van De Velde LA; Li Y; Flynn PM; McCullers JA
    Vaccine; 2012 Jan; 30(5):879-85. PubMed ID: 22155630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
    Tsurudome Y; Kimachi K; Okada Y; Matsuura K; Ooyama Y; Ibaragi K; Kino Y; Ueda K
    Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced immune response after a second dose of an AS03-adjuvanted H1N1 influenza A vaccine in patients after hematopoietic stem cell transplantation.
    Gueller S; Allwinn R; Mousset S; Martin H; Wieters I; Herrmann E; Serve H; Bickel M; Bug G
    Biol Blood Marrow Transplant; 2011 Oct; 17(10):1546-50. PubMed ID: 21324375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longitudinal analysis of the peripheral B cell repertoire reveals unique effects of immunization with a new influenza virus strain.
    Cortina-Ceballos B; Godoy-Lozano EE; Téllez-Sosa J; Ovilla-Muñoz M; Sámano-Sánchez H; Aguilar-Salgado A; Gómez-Barreto RE; Valdovinos-Torres H; López-Martínez I; Aparicio-Antonio R; Rodríguez MH; Martínez-Barnetche J
    Genome Med; 2015 Nov; 7():124. PubMed ID: 26608341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.
    Gilca V; De Serres G; Hamelin ME; Boivin G; Ouakki M; Boulianne N; Sauvageau C; Dionne M; Gilca R; Skowronski D
    Vaccine; 2011 Dec; 30(1):35-41. PubMed ID: 22063386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial.
    Plennevaux E; Blatter M; Cornish MJ; Go K; Kirby D; Wali M; Reeves-Hoché MK; Denis M
    Vaccine; 2011 Feb; 29(8):1569-75. PubMed ID: 21219979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nine μg intradermal influenza vaccine and 15 μg intramuscular influenza vaccine induce similar cellular and humoral immune responses in adults.
    Nougarede N; Bisceglia H; Rozières A; Goujon C; Boudet F; Laurent P; Vanbervliet B; Rodet K; Hennino A; Nicolas JF
    Hum Vaccin Immunother; 2014; 10(9):2713-20. PubMed ID: 25483667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers.
    Low JG; Lee LS; Ooi EE; Ethirajulu K; Yeo P; Matter A; Connolly JE; Skibinski DA; Saudan P; Bachmann M; Hanson BJ; Lu Q; Maurer-Stroh S; Lim S; Novotny-Diermayr V
    Vaccine; 2014 Sep; 32(39):5041-8. PubMed ID: 25045806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.
    Reisinger KS; Holmes SJ; Pedotti P; Arora AK; Lattanzi M
    Hum Vaccin Immunother; 2014; 10(8):2395-407. PubMed ID: 25424947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Pediatr Infect Dis J; 2014 Dec; 33(12):e320-9. PubMed ID: 24978857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunization with a low dose of hemagglutinin-encoding plasmid protects against 2009 H1N1 pandemic influenza virus in mice.
    Fang J; Chen Z; Liu X; Li H; Wang J; Shen X; Chen W; Liu Y; Wang Y; Zhao P; Qi Z
    J Virol Methods; 2011 May; 173(2):314-9. PubMed ID: 21392537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination.
    Cox RJ; Brokstad KA; Zuckerman MA; Wood JM; Haaheim LR; Oxford JS
    Vaccine; 1994 Aug; 12(11):993-9. PubMed ID: 7975853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Compatibility of ASO3-adjuvanted H1N1pdm09 and seasonal trivalent influenza vaccines in adults: results of a randomized, controlled trial.
    Scheifele DW; Ward BJ; Dionne M; Vanderkooi OG; Loeb M; Coleman BL; Li Y;
    Vaccine; 2012 Jul; 30(32):4728-32. PubMed ID: 22652402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.